

Roza Badr Eslam MD, PD

Department of Cardiology

AKH-Vienna, Medical University of Vienna, Austria

Tel : +43-1-40400-4614-0

Fax : +43-1-40400-4216-0

Mobile : +43-650 437 2426

Email; roza.badreslam@meduniwien.ac.at

Specialty: Cardiovascular Medicine

Academic Information

Education:

- Medical University of Vienna/ Austria, 2004, MD
- Residency: Internal Medicine/ Medical University of Vienna/ Austria
- Fellowship: Cardiology/ Medical University of Vienna/ Austria
- Certifications: Internal Medicine, Austrian board exam 2012
Austrian Echocardiography exam 2012
- Master Degree in pulmonary vascular disease, University of Bologna, Italy 2013
- Venia docendi , Medical University of Vienna / Austria 2016
- Postdoctoral research fellow in Pulmonary Vascular Disease Program
Brigham and Women's Hospital, Harvard Medical School,
Boston, Massachusetts USA
- Adjunc Professor "apl. Professor" at medical University of Vienna 2022

Clinical Interests:

- Internal medicine
- Cardiology
- Coronary artery disease
- Heart Failure / HCM
- ATTR-CM
- Pulmonary vascular diseases
- Exercised induced pulmonary hypertension

Major Research Interests:

- Thrombosis research, understanding the platelet activation pathways
- Anticoagulation, platelet aggregation, platelet aggregation inhibitor, platelet function test
- Heart Failure / cardiac Amyloidosis
- Understand the pathophysiology of pulmonary vascular disease
- Study and identify characteristics of stem cells to apply to clinical disorders

Teaching:

- Austrian Medical teaching certification 2011
- Mentor in ScientMedNet Mentoring Program, Medical University of Vienna/ Austria, 2012
- Senior Mentoring Program, Medical University of Vienna/ Austria, 2013 -ongoing

Research Support/Grants:

- 2013 Austrian science fund, Erwin Schrödinger Fellowship Program, Grant Number: J3522-B13
- 2022 Government-Fund “Bürgermeisterfonds”; Project-nr. 22005

Training:

- Collaborative Institutional Training Initiative (CITI Program) 2015
- Introduction to Clinical Investigation, Harvard Catalyst 2015
- Good clinical Training 2010 ,2015, 2016 ,2017, 2020 and 2022
- Maximizing the Mentee-Mentor Relationship, Harvard Catalyst 2016

Manuscript Reviews:

- Platelets
- Journal of Interventional Cardiology
- Wiener klinischen Wochenschrift
- Pulmonary Circulation

Membership:

- Austrian Society of Cardiology (OEKG)
- European Society of Cardiology (ESC)
- American Thoracics Society (ATS)

Awards:

- Basic science award, Max-Schaldach, Austrian Society of Cardiology 2010

Research:

- Research associate at cardiology department , AKH Vienna/Austria
- Study coordinator and sub investigator of multicenter clinical trials and registers (since 2005)
- Collaborating in Pulmonary Vascular Disease Research and Clinical Care Tissue Bank, Brigham and Women’s Hospital, Boston MA, USA (Principal Investigator: Aaron Waxman, MD, PHD) 2015

PRINCIPAL INVESTIGATOR (PI) for the following international multicenter, phase II and III studi

1. AMETHYST (AstraZeneca): A Multicenter, Double-Blind, Placebo and Active Control Efficacy and Safety Study to Evaluate Verinurad combined with Allopurinol in Heart Failure with Preserved Ejection Fraction
2. ODYSSEY-HCM (Bristol Myers Squibb): A Double-Blind, Randomized, Placebo-Controlled Study to Evaluate Mavacamten in Adults with Symptomatic Non-obstructive Hypertrophic Cardiomyopathy
- * 3. ALXN2220-ATTRCM-301; A Phase 3, Randomized, Double-Blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Amyloid Depleter ALXN2220 in Adult Participants with Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
4. BaxHTN (A randomized, double-blind, placebo-controlled clinical parallel-group trial to evaluate the efficacy and safety of Baxdrostat in participants with uncontrolled hypertension on two or more medications, including participants with resistant hypertension)
5. Balance-D HF (A Phase III, Randomized, Double-blind Study to Evaluate the Effect of Balcinrenone/Dapagliflozin, Compared to Dapagliflozin, on the Risk of Heart Failure Events and Cardiovascular Death in Patients with Heart Failure and Impaired Kidney Function)
6. DISCOVER-HCM (DELIVER INSIGHTS IN HYPERTROPHIC CARDIOMYOPATHY AND OBSERVATIONAL OUTCOMES IN REAL WORLD)

Deputy-PI for the following international multicenter, phase II and III studies:

1. 1DYNAMIC (Medical University of Vienna): Evaluation of the pharmacodynamic effects of riociguat in subjects with pulmonary hypertension and heart failure with preserved ejection fraction in a randomized, double blind, placebo controlled, parallel group, multicenter study.
2. ION (Ionis Pharmaceuticals, Inc): A Phase 3 Global, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ION-682884 in Patients with Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM) (ongoing)
3. SPIRIT - HF (Charité): SPIRonolactone in the Treatment of Heart Failure. A double-blind, randomized, placebo-controlled, parallel group, interventional phase III study to evaluate the efficacy and safety of spironolactone compared to placebo on the composite endpoint of recurrent heart failure hospitalizations and cardiovascular death in patients with heart failure with mid- range or preserved ejection fraction (ongoing)

Sub Investigator for the following international multicenter, phase II and III studies:

1. SERENADE OL (Janssen): A long-term, multicenter, single-arm, open-label extension of the SERENADE study, to assess the safety and efficacy of macitentan in subjects with heart failure with preserved ejection fraction and pulmonary vascular disease. (ongoing)

2. SOLOIST (Sanofi): A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Effects of Sotagliflozin on Clinical Outcomes in Hemodynamically Stable Patients with Type 2 Diabetes POST Worsening Heart Failure
3. BMAD HF (ZOLL Services LLC): Benefits of MicroCor (μ Cor™) in ambulatory decompensated heart failure.
4. BMAD TX (ZOLL Services LLC): BENEFITS OF MICROCOR (uCor) in ambulatory decompensated heart failure.
5. HELIOS B (ALNYLAM): A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Vutrisiran in Patients with Transthyretin Amyloidosis with Cardiomyopathy (ATTR Amyloidosis with Cardiomyopathy) (ongoing)
6. FINEARTS (BAYER) Efficacy and safety of Finerenone in participants with symptomatic heart failure and left ventricular ejection fraction $\geq 40\%$ (LVEF $\geq 40\%$)
7. ROR-PH-302 (ADVANCE CAPACITY): A Phase 3, clinical trial evaluating the effect of the drug ralinepag on exercise capacity in patients with PULMONARY ARTERIAL HYPERTENSION (PAH)